FADS1 modulates metabolic syndrome in schizophrenia patients receiving olanzapine monotherapy.
In this study, we hypothesized that fatty acid desaturase-1 (FADS1) and fatty acid desaturase-2 (FADS2) may mediate metabolic syndrome (MetS) in patients receiving olanzapine monotherapy. 216 schizophrenia patients were recruited. There is a significant difference between the patients with or without MetS in term of the expression of FADS1 mRNA (Fā=ā4.58, Pā=ā0.03), but not FADS2 mRNA (Fā=ā1.29, Pā=ā0.26). We observed a positive association between FADS1 mRNA and high-density lipoprotein cholesterol (Pā=ā0.04), and a negative association between FADS1 mRNA and systolic blood pressure (Pā=ā0.04). Our findings implied that FADS1 may be an important genetic modifier that can regulate olanzapine-associated metabolic disturbance.
PMID: 32801079 [PubMed - as supplied by publisher]
Source: Asian Journal of Psychiatry - Category: Psychiatry Tags: Asian J Psychiatr Source Type: research
More News: Cholesterol | Genetics | Metabolic Syndrome | Psychiatry | Schizophrenia | Study | Zyprexa